Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma.

Wright TM, Rathmell WK.

J Biol Chem. 2010 Apr 23;285(17):12916-24. doi: 10.1074/jbc.M109.073924. Epub 2010 Feb 25.

3.

Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR.

Eur Urol. 2016 Apr;69(4):646-57. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19. Review.

6.
7.

PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.

Petrella BL, Brinckerhoff CE.

Cancer Biol Ther. 2009 Jul;8(14):1389-401. Epub 2009 Jul 30.

8.

Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.

Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH, Esteban MA.

Oncogene. 2012 Feb 23;31(8):1065-72. doi: 10.1038/onc.2011.305. Epub 2011 Aug 15.

PMID:
21841824
9.

The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.

Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H.

J Pathol. 2013 Mar;229(4):525-34. doi: 10.1002/path.4107. Epub 2013 Jan 21.

PMID:
23007793
10.

(1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.

Cuperlovic-Culf M, Cormier K, Touaibia M, Reyjal J, Robichaud S, Belbraouet M, Turcotte S.

Int J Cancer. 2016 May 15;138(10):2439-49. doi: 10.1002/ijc.29947. Epub 2016 Jan 29.

11.

Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.

Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Melillo G, Konishi I.

Hum Pathol. 2007 Sep;38(9):1310-20. Epub 2007 Jun 6. Erratum in: Hum Pathol. 2008 Jan;39(1):147. Mellilo, Giovanni [corrected to Melillo, Giovanni].

PMID:
17555795
12.

Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M.

Carcinogenesis. 2007 Mar;28(3):529-36. Epub 2006 Aug 18.

PMID:
16920734
13.

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.

Mol Cell Biol. 2005 Jul;25(13):5675-86.

14.

[The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].

Gong K, Zhang N, Na X, Wu G, Yang XY, Xin DQ, Na YQ.

Zhonghua Wai Ke Za Zhi. 2005 Mar 15;43(6):390-3. Chinese.

PMID:
15854350
15.

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S.

Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23.

17.

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.

18.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
19.

Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL.

Cancer Res. 2002 May 15;62(10):2957-61.

20.

VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.

Nyhan MJ, El Mashad SM, O'Donovan TR, Ahmad S, Collins C, Sweeney P, Rogers E, O'Sullivan GC, McKenna SL.

Anal Cell Pathol (Amst). 2010;33(3):121-32. doi: 10.3233/ACP-CLO-2010-0541.

Supplemental Content

Support Center